Analyst Price Target is $27.00
▲ +96.08% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lantern Pharma in the last 3 months. The average price target is $27.00, with a high forecast of $29.00 and a low forecast of $25.00. The average price target represents a 96.08% upside from the last price of $13.77.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Lantern Pharma.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.